The Effect of Omega-3 prescription on serum levels of Interleukin-6 and Interleukin-1 beta in patients with traumatic brain injury

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180223038838N1

Enrollment

Registered

2018-03-10

Start date

2018-03-11

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

traumatic brain injury. Diffuse traumatic brain injury

Interventions

Intervention 1: Intervention group: Recipient of oral Omega 3 capsule. Intervention 2: Control group: Recipient of oral placebo capsule.

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with traumatic brain injur

Exclusion criteria

Exclusion criteria: History of seafood susceptibility History of severe and uncontrollable hypertension Consumption of immunosuppression Consumption of antiepileptic Liver Dysfunction Kidney disorder

Design outcomes

Primary

Measure	Time frame
Glasgow Coma Scale. Timepoint: Before the intervention and seven days after the intervention. Method of measurement: Glasgow coma scale score.;Serum level of interleukin-6. Timepoint: Before the intervention and seven days after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA ).;Serum level of interleukin-1 beta. Timepoint: Before the intervention and seven days after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA ).	—

Measure

Time frame

Glasgow Coma Scale. Timepoint: Before the intervention and seven days after the intervention. Method of measurement: Glasgow coma scale score.;Serum level of interleukin-6. Timepoint: Before the intervention and seven days after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA ).;Serum level of interleukin-1 beta. Timepoint: Before the intervention and seven days after the intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA ).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fereshteh Amiri

Ahvaz University of Medical Sciences

amiri.fe@ajums.ac.ir+98 61 3333 8989

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026